世界の血液悪性腫瘍におけるCAR-T療法市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global CAR-T Therapy in Haematological Malignancy Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-3975
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、105ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、血液悪性腫瘍におけるCAR-T療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（同種異系型、自家型）、用途別市場規模（病院、がん研究センター、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・血液悪性腫瘍におけるCAR-T療法の市場動向
・企業の競争状況、市場シェア
・血液悪性腫瘍におけるCAR-T療法の種類別市場規模と予測2016-2027（同種異系型、自家型）
・血液悪性腫瘍におけるCAR-T療法の用途別市場規模と予測2016-2027（病院、がん研究センター、その他）
・血液悪性腫瘍におけるCAR-T療法の北米市場規模2016-2027（アメリカ、カナダ）
・血液悪性腫瘍におけるCAR-T療法の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・血液悪性腫瘍におけるCAR-T療法のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・血液悪性腫瘍におけるCAR-T療法の中南米市場規模2016-2027（メキシコ、ブラジル）
・血液悪性腫瘍におけるCAR-T療法の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Celgene (Juno Therapeutics)、Novartis、Gilead (Kite Pharma)、Pfizer、CARsgen Therapeutics、Autolus Therapeutics、Aurora BioPharma、Sorrento Therapeutics、Mustang Bio、Bluebird Bio、Collectis、Allogene Therapeutics、Celyad）
・結論

Market Analysis and Insights: Global CAR-T Therapy in Haematological Malignancy Market
The global CAR-T Therapy in Haematological Malignancy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global CAR-T Therapy in Haematological Malignancy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global CAR-T Therapy in Haematological Malignancy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global CAR-T Therapy in Haematological Malignancy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global CAR-T Therapy in Haematological Malignancy market.

Global CAR-T Therapy in Haematological Malignancy Scope and Market Size
CAR-T Therapy in Haematological Malignancy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global CAR-T Therapy in Haematological Malignancy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Allogeneic
Autologous

Segment by Application
Hospitals
Cancer Research Centers
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Celgene (Juno Therapeutics)
Novartis
Gilead (Kite Pharma)
Pfizer
CARsgen Therapeutics
Autolus Therapeutics
Aurora BioPharma
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Collectis
Allogene Therapeutics
Celyad

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Allogeneic
1.2.3 Autologous
1.3 Market by Application
1.3.1 Global CAR-T Therapy in Haematological Malignancy Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Cancer Research Centers
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global CAR-T Therapy in Haematological Malignancy Market Perspective (2016-2027)
2.2 CAR-T Therapy in Haematological Malignancy Growth Trends by Regions
2.2.1 CAR-T Therapy in Haematological Malignancy Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 CAR-T Therapy in Haematological Malignancy Historic Market Share by Regions (2016-2021)
2.2.3 CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Regions (2022-2027)
2.3 CAR-T Therapy in Haematological Malignancy Industry Dynamic
2.3.1 CAR-T Therapy in Haematological Malignancy Market Trends
2.3.2 CAR-T Therapy in Haematological Malignancy Market Drivers
2.3.3 CAR-T Therapy in Haematological Malignancy Market Challenges
2.3.4 CAR-T Therapy in Haematological Malignancy Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Revenue
3.1.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Revenue (2016-2021)
3.1.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2016-2021)
3.2 Global CAR-T Therapy in Haematological Malignancy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by CAR-T Therapy in Haematological Malignancy Revenue
3.4 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio
3.4.1 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR-T Therapy in Haematological Malignancy Revenue in 2020
3.5 CAR-T Therapy in Haematological Malignancy Key Players Head office and Area Served
3.6 Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service
3.7 Date of Enter into CAR-T Therapy in Haematological Malignancy Market
3.8 Mergers & Acquisitions, Expansion Plans

4 CAR-T Therapy in Haematological Malignancy Breakdown Data by Type
4.1 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Type (2016-2021)
4.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2022-2027)

5 CAR-T Therapy in Haematological Malignancy Breakdown Data by Application
5.1 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Application (2016-2021)
5.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America CAR-T Therapy in Haematological Malignancy Market Size (2016-2027)
6.2 North America CAR-T Therapy in Haematological Malignancy Market Size by Type
6.2.1 North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021)
6.2.2 North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027)
6.2.3 North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2027)
6.3 North America CAR-T Therapy in Haematological Malignancy Market Size by Application
6.3.1 North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021)
6.3.2 North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027)
6.3.3 North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2027)
6.4 North America CAR-T Therapy in Haematological Malignancy Market Size by Country
6.4.1 North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021)
6.4.2 North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe CAR-T Therapy in Haematological Malignancy Market Size (2016-2027)
7.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type
7.2.1 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021)
7.2.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027)
7.2.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2027)
7.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application
7.3.1 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021)
7.3.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027)
7.3.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2027)
7.4 Europe CAR-T Therapy in Haematological Malignancy Market Size by Country
7.4.1 Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021)
7.4.2 Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size (2016-2027)
8.2 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Type
8.2.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021)
8.2.2 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027)
8.2.3 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2027)
8.3 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Application
8.3.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021)
8.3.2 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027)
8.3.3 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2027)
8.4 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region
8.4.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2016-2021)
8.4.2 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America CAR-T Therapy in Haematological Malignancy Market Size (2016-2027)
9.2 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Type
9.2.1 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021)
9.2.2 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027)
9.2.3 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2027)
9.3 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Application
9.3.1 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021)
9.3.2 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027)
9.3.3 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2027)
9.4 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country
9.4.1 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021)
9.4.2 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size (2016-2027)
10.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type
10.2.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021)
10.2.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027)
10.2.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2027)
10.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application
10.3.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021)
10.3.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027)
10.3.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2027)
10.4 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country
10.4.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021)
10.4.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Celgene (Juno Therapeutics)
11.1.1 Celgene (Juno Therapeutics) Company Details
11.1.2 Celgene (Juno Therapeutics) Business Overview
11.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Introduction
11.1.4 Celgene (Juno Therapeutics) Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
11.1.5 Celgene (Juno Therapeutics) Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis CAR-T Therapy in Haematological Malignancy Introduction
11.2.4 Novartis Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 Gilead (Kite Pharma)
11.3.1 Gilead (Kite Pharma) Company Details
11.3.2 Gilead (Kite Pharma) Business Overview
11.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Introduction
11.3.4 Gilead (Kite Pharma) Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
11.3.5 Gilead (Kite Pharma) Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Introduction
11.4.4 Pfizer Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 CARsgen Therapeutics
11.5.1 CARsgen Therapeutics Company Details
11.5.2 CARsgen Therapeutics Business Overview
11.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
11.5.4 CARsgen Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
11.5.5 CARsgen Therapeutics Recent Development
11.6 Autolus Therapeutics
11.6.1 Autolus Therapeutics Company Details
11.6.2 Autolus Therapeutics Business Overview
11.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
11.6.4 Autolus Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
11.6.5 Autolus Therapeutics Recent Development
11.7 Aurora BioPharma
11.7.1 Aurora BioPharma Company Details
11.7.2 Aurora BioPharma Business Overview
11.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Introduction
11.7.4 Aurora BioPharma Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
11.7.5 Aurora BioPharma Recent Development
11.8 Sorrento Therapeutics
11.8.1 Sorrento Therapeutics Company Details
11.8.2 Sorrento Therapeutics Business Overview
11.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
11.8.4 Sorrento Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
11.8.5 Sorrento Therapeutics Recent Development
11.9 Mustang Bio
11.9.1 Mustang Bio Company Details
11.9.2 Mustang Bio Business Overview
11.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Introduction
11.9.4 Mustang Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
11.9.5 Mustang Bio Recent Development
11.10 Bluebird Bio
11.10.1 Bluebird Bio Company Details
11.10.2 Bluebird Bio Business Overview
11.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Introduction
11.10.4 Bluebird Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
11.10.5 Bluebird Bio Recent Development
11.11 Collectis
11.11.1 Collectis Company Details
11.11.2 Collectis Business Overview
11.11.3 Collectis CAR-T Therapy in Haematological Malignancy Introduction
11.11.4 Collectis Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
11.11.5 Collectis Recent Development
11.12 Allogene Therapeutics
11.12.1 Allogene Therapeutics Company Details
11.12.2 Allogene Therapeutics Business Overview
11.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
11.12.4 Allogene Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
11.12.5 Allogene Therapeutics Recent Development
11.13 Celyad
11.13.1 Celyad Company Details
11.13.2 Celyad Business Overview
11.13.3 Celyad CAR-T Therapy in Haematological Malignancy Introduction
11.13.4 Celyad Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
11.13.5 Celyad Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Allogeneic
Table 3. Key Players of Autologous
Table 4. Global CAR-T Therapy in Haematological Malignancy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions (2016-2021)
Table 8. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions (2022-2027)
Table 10. CAR-T Therapy in Haematological Malignancy Market Trends
Table 11. CAR-T Therapy in Haematological Malignancy Market Drivers
Table 12. CAR-T Therapy in Haematological Malignancy Market Challenges
Table 13. CAR-T Therapy in Haematological Malignancy Market Restraints
Table 14. Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global CAR-T Therapy in Haematological Malignancy Market Share by Players (2016-2021)
Table 16. Global Top CAR-T Therapy in Haematological Malignancy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2020)
Table 17. Ranking of Global Top CAR-T Therapy in Haematological Malignancy Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by CAR-T Therapy in Haematological Malignancy Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service
Table 21. Date of Enter into CAR-T Therapy in Haematological Malignancy Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021) (US$ Million)
Table 24. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2016-2021)
Table 25. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Application (2016-2021)
Table 29. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021) (US$ Million)
Table 32. North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021) (US$ Million)
Table 34. North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2022-2027) & (US$ Million)
Table 61. Celgene (Juno Therapeutics) Company Details
Table 62. Celgene (Juno Therapeutics) Business Overview
Table 63. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product
Table 64. Celgene (Juno Therapeutics) Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
Table 65. Celgene (Juno Therapeutics) Recent Development
Table 66. Novartis Company Details
Table 67. Novartis Business Overview
Table 68. Novartis CAR-T Therapy in Haematological Malignancy Product
Table 69. Novartis Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
Table 70. Novartis Recent Development
Table 71. Gilead (Kite Pharma) Company Details
Table 72. Gilead (Kite Pharma) Business Overview
Table 73. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product
Table 74. Gilead (Kite Pharma) Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
Table 75. Gilead (Kite Pharma) Recent Development
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer CAR-T Therapy in Haematological Malignancy Product
Table 79. Pfizer Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. CARsgen Therapeutics Company Details
Table 82. CARsgen Therapeutics Business Overview
Table 83. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product
Table 84. CARsgen Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
Table 85. CARsgen Therapeutics Recent Development
Table 86. Autolus Therapeutics Company Details
Table 87. Autolus Therapeutics Business Overview
Table 88. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product
Table 89. Autolus Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
Table 90. Autolus Therapeutics Recent Development
Table 91. Aurora BioPharma Company Details
Table 92. Aurora BioPharma Business Overview
Table 93. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product
Table 94. Aurora BioPharma Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
Table 95. Aurora BioPharma Recent Development
Table 96. Sorrento Therapeutics Company Details
Table 97. Sorrento Therapeutics Business Overview
Table 98. Sorrento Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
Table 99. Sorrento Therapeutics Recent Development
Table 100. Mustang Bio Company Details
Table 101. Mustang Bio Business Overview
Table 102. Mustang Bio CAR-T Therapy in Haematological Malignancy Product
Table 103. Mustang Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
Table 104. Mustang Bio Recent Development
Table 105. Bluebird Bio Company Details
Table 106. Bluebird Bio Business Overview
Table 107. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product
Table 108. Bluebird Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
Table 109. Bluebird Bio Recent Development
Table 110. Collectis Company Details
Table 111. Collectis Business Overview
Table 112. Collectis CAR-T Therapy in Haematological Malignancy Product
Table 113. Collectis Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
Table 114. Collectis Recent Development
Table 115. Allogene Therapeutics Company Details
Table 116. Allogene Therapeutics Business Overview
Table 117. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product
Table 118. Allogene Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
Table 119. Allogene Therapeutics Recent Development
Table 120. Celyad Company Details
Table 121. Celyad Business Overview
Table 122. Celyad CAR-T Therapy in Haematological Malignancy Product
Table 123. Celyad Revenue in CAR-T Therapy in Haematological Malignancy Business (2016-2021) & (US$ Million)
Table 124. Celyad Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CAR-T Therapy in Haematological Malignancy Market Share by Type: 2020 VS 2027
Figure 2. Allogeneic Features
Figure 3. Autologous Features
Figure 4. Global CAR-T Therapy in Haematological Malignancy Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Cancer Research Centers Case Studies
Figure 7. Others Case Studies
Figure 8. CAR-T Therapy in Haematological Malignancy Report Years Considered
Figure 9. Global CAR-T Therapy in Haematological Malignancy Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global CAR-T Therapy in Haematological Malignancy Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions: 2020 VS 2027
Figure 12. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions (2022-2027)
Figure 13. Global CAR-T Therapy in Haematological Malignancy Market Share by Players in 2020
Figure 14. Global Top CAR-T Therapy in Haematological Malignancy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2020
Figure 15. The Top 10 and 5 Players Market Share by CAR-T Therapy in Haematological Malignancy Revenue in 2020
Figure 16. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2016-2021)
Figure 17. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2022-2027)
Figure 18. North America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America CAR-T Therapy in Haematological Malignancy Market Share by Type (2016-2027)
Figure 20. North America CAR-T Therapy in Haematological Malignancy Market Share by Application (2016-2027)
Figure 21. North America CAR-T Therapy in Haematological Malignancy Market Share by Country (2016-2027)
Figure 22. United States CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe CAR-T Therapy in Haematological Malignancy Market Share by Type (2016-2027)
Figure 26. Europe CAR-T Therapy in Haematological Malignancy Market Share by Application (2016-2027)
Figure 27. Europe CAR-T Therapy in Haematological Malignancy Market Share by Country (2016-2027)
Figure 28. Germany CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Share by Type (2016-2027)
Figure 36. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Share by Application (2016-2027)
Figure 37. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Share by Region (2016-2027)
Figure 38. China CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America CAR-T Therapy in Haematological Malignancy Market Share by Type (2016-2027)
Figure 46. Latin America CAR-T Therapy in Haematological Malignancy Market Share by Application (2016-2027)
Figure 47. Latin America CAR-T Therapy in Haematological Malignancy Market Share by Country (2016-2027)
Figure 48. Mexico CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Share by Type (2016-2027)
Figure 52. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Share by Application (2016-2027)
Figure 53. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Share by Country (2016-2027)
Figure 54. Turkey CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Celgene (Juno Therapeutics) Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
Figure 58. Novartis Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
Figure 59. Gilead (Kite Pharma) Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
Figure 60. Pfizer Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
Figure 61. CARsgen Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
Figure 62. Autolus Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
Figure 63. Aurora BioPharma Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
Figure 64. Sorrento Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
Figure 65. Mustang Bio Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
Figure 66. Bluebird Bio Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
Figure 67. Collectis Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
Figure 68. Allogene Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
Figure 69. Celyad Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

以下、関連資料のご紹介

世界のT細胞療法市場規模・現状・予測（2021年-2027年）

Global T-Cell Therapy Market Size, Status and Forecast 2021-2027
QFJ1-4937 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、T細胞療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（CAR T細胞療法、TCR療法、TIL療法）、用途別市場規模（病院、診療所・外来センター、がん研究所、その他）、主要地域別市場規模（北米、アメ...

世界の自己細胞療法市場規模・現状・予測（2021年-2027年）

Global Autologous Cell Therapy Market Size, Status and Forecast 2021-2027
QFJ1-3873 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、自己細胞療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（骨髄、表皮）、用途別市場規模（神経内科、整形外科、がん、創傷治癒、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓...

世界のTCR療法市場規模・現状・予測（2021年-2027年）

Global TCR Therapy Market Size, Status and Forecast 2021-2027
QFJ1-4939 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、TCR療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（キメラ抗原受容体シグナル伝達、TCRα/βヘテロダイマーシグナル伝達）、用途別市場規模（病院、診療所・外来センター、がん研究所、その他）、主要...

世界の遺伝子治療医学市場規模・現状・予測（2021年-2027年）

Global Gene Therapy Medicine Market Size, Status and Forecast 2021-2027
QFJ1-5751 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、遺伝子治療医学の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口、注射）、用途別市場規模（がん、単発性、感染症、循環器疾患、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓...

世界の遺伝性遺伝性疾患用遺伝子治療市場規模・現状・予測（2021年-2027年）

Global Gene Therapy for Inherited Genetic Disorders Market Size, Status and Forecast 2021-2027
QFJ1-4248 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、遺伝性遺伝性疾患用遺伝子治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（眼疾患、造血系疾患、中枢神経系疾患、筋肉疾患、その他）、用途別市場規模（病院、診療所、研究所、その他）、主要地域別市場規模（...

世界の遺伝子治療薬市場規模・現状・予測（2021年-2027年）

Global Gene Therapy Drugs Market Size, Status and Forecast 2021-2027
QFJ1-5749 2021年6月 108Pages
QYResearch社発行の本調査レポートでは、遺伝子治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（神経筋疾患、遺伝病、その他）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南...

世界の抗老化療法市場規模・現状・予測（2021年-2027年）

Global Anti-Senescence Therapy Market Size, Status and Forecast 2021-2027
QFJ1-3836 2021年6月 108Pages
QYResearch社発行の本調査レポートでは、抗老化療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（遺伝子治療、免疫療法、その他）、用途別市場規模（循環器疾患、神経変性疾患、眼科疾患、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア...

世界の遺伝子治療医薬品（GTMP）市場規模・現状・予測（2021年-2027年）

Global Gene Therapy Medicinal Products (GTMP) Market Size, Status and Forecast 2021-2027
QFJ1-5750 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、遺伝子治療医薬品（GTMP）の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口、注射）、用途別市場規模（がん、単発性、感染症、循環器疾患、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、...

世界の長寿＆老化防止治療市場規模・現状・予測（2021年-2027年）

Global Longevity and Anti-senescence Therapy Market Size, Status and Forecast 2021-2027
QFJ1-4440 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、長寿＆老化防止治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（溶血性薬物療法、遺伝子治療、免疫療法、その他幹細胞治療）、用途別市場規模（病院、医療機関、医薬品・機器販売）、主要地域別市場規模（北米...

世界の個別化細胞療法市場規模・現状・予測（2021年-2027年）

Global Personalized Cell Therapy Market Size, Status and Forecast 2021-2027
QFJ1-4691 2021年6月 108Pages
QYResearch社発行の本調査レポートでは、個別化細胞療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（造血幹細胞、骨格筋幹細胞、間葉系幹細胞、リンパ球、その他）、用途別市場規模（循環器疾患、神経疾患、炎症性疾患、糖尿病、がん、その他）、主要...

世界の自己細胞療法市場規模・現状・予測（2021年-2027年） Autologous cell therapy refers to the injection or delivery of human tissue or cells to the same person to treat pathological conditions. For the same purpose, the stem cells are taken out of the patient, harvested, cultured, and transplanted again to the same person. The purpose of this method is t…
世界の自己調整血漿療法市場規模・現状・予測（2021年-2027年） Autologous conditioned plasma therapy is used to treat a range of problems, such as musculoskeletal injuries, sports injuries and trauma. Today, among other things, it is widely used to treat skin ulcers, sports injuries, and cosmetic surgery. The growing demand for user-friendly treatment procedure…
世界の同種異系幹細胞治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Allogeneic Stem Cell Therapy Market The global Allogeneic Stem Cell Therapy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integri…
世界のがん点滴療法市場規模・現状・予測（2021年-2027年） Cancer treatments often require infusion treatments, like chemotherapy. Market Analysis and Insights: Global Cancer Infusion Therapy Market The global Cancer Infusion Therapy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. Wi…
世界の肺がん治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Lung Cancer Therapy Market The global Lung Cancer Therapy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report mak…